Nano Cap New Millennium Growth Fund L P Takes $401,000 Position in Harvard Bioscience, Inc. $HBIO

Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 600,000 shares of the medical instruments supplier’s stock, valued at approximately $401,000.

A number of other large investors have also recently modified their holdings of HBIO. Bank of America Corp DE boosted its stake in shares of Harvard Bioscience by 44.4% during the 4th quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock valued at $82,000 after purchasing an additional 11,948 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of Harvard Bioscience by 7.8% during the 1st quarter. Acadian Asset Management LLC now owns 1,077,069 shares of the medical instruments supplier’s stock valued at $606,000 after purchasing an additional 78,276 shares in the last quarter. Strs Ohio bought a new stake in shares of Harvard Bioscience during the 1st quarter valued at about $117,000. Marshall Wace LLP bought a new stake in shares of Harvard Bioscience during the 2nd quarter valued at about $61,000. Finally, Jane Street Group LLC boosted its stake in shares of Harvard Bioscience by 491.9% during the 2nd quarter. Jane Street Group LLC now owns 70,736 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 58,785 shares in the last quarter. Institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Stock Performance

HBIO stock opened at $5.52 on Friday. The stock has a market capitalization of $24.90 million, a PE ratio of -2.54 and a beta of 1.57. Harvard Bioscience, Inc. has a 12-month low of $2.81 and a 12-month high of $9.50. The company has a current ratio of 1.99, a quick ratio of 1.06 and a debt-to-equity ratio of 3.60. The stock’s 50 day simple moving average is $5.62 and its 200 day simple moving average is $6.05.

Harvard Bioscience (NASDAQ:HBIO) last released its quarterly earnings data on Tuesday, May 12th. The medical instruments supplier reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.29. The business had revenue of $20.76 million for the quarter, compared to analysts’ expectations of $21.20 million. Harvard Bioscience had a negative return on equity of 25.78% and a negative net margin of 11.44%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on HBIO shares. Benchmark reduced their price target on Harvard Bioscience from $20.00 to $6.00 and set a “speculative buy” rating on the stock in a research note on Friday, March 13th. New Street Research set a $6.00 price target on Harvard Bioscience in a research note on Friday, March 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Harvard Bioscience in a research note on Friday, March 27th. Finally, Wall Street Zen cut Harvard Bioscience from a “buy” rating to a “hold” rating in a research note on Saturday, March 21st. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $6.00.

Insider Activity at Harvard Bioscience

In other Harvard Bioscience news, Director Stephen J. Denelsky acquired 10,000 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were acquired at an average cost of $4.87 per share, with a total value of $48,700.00. Following the transaction, the director owned 21,000 shares of the company’s stock, valued at $102,270. The trade was a 90.91% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director William Snider purchased 12,525 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were bought at an average cost of $4.99 per share, for a total transaction of $62,499.75. Following the acquisition, the director owned 23,525 shares in the company, valued at approximately $117,389.75. The trade was a 113.86% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have acquired 36,000 shares of company stock valued at $177,354. 20.30% of the stock is owned by corporate insiders.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.